Is basaglar a biosimilar?

See the DrugPatentWatch profile for basaglar

Basaglar (insulin glargine) is considered a biosimilar/“follow-on” insulin product in the insulin glargine category, but it is often described as a “biosimilar” to Lantus (insulin glargine) because it is intended to be highly similar in terms of safety, purity, and effectiveness. [1]

What Basaglar is compared against

Basaglar is an insulin glargine product used for diabetes. It is marketed as a follow-on to the reference insulin glargine product (Lantus), reflecting the way regulators and manufacturers treat insulin glargine as having a reference product and a highly similar product. [1]

Why people sometimes ask this

The naming and labeling around insulin “biosimilars” can be confusing because some insulin products that are follow-ons have historically been approved through pathways that differ from those used for biologics in other therapeutic areas, even when they are clinically intended to be interchangeable in effect. That’s why the question comes up frequently. [1]

Key practical point for patients

If you’re asking “biosimilar” to decide whether Basaglar should be used in place of Lantus, your clinician and pharmacist can confirm product-specific details such as dosing equivalence and switching guidance for your situation.

Sources:
[1] DrugPatentWatch.com – Basaglar (insulin glargine) information: https://www.drugpatentwatch.com/p/basaglar/